by Clinical Neuropsychologist Online | Wednesday, August 21, 2024 | Dementia
Abstract INTRODUCTION CT1812 is in clinical development for the treatment of Alzheimer’s disease (AD). Cerebrospinal fluid (CSF) exploratory proteomics was employed to identify pharmacodynamic biomarkers of CT1812 in mild to moderate AD from two independent...
by Clinical Neuropsychologist Online | Wednesday, August 21, 2024 | Dementia
Abstract Neurogenesis persists throughout adulthood in the hippocampus and contributes to specific cognitive functions. In Alzheimer’s disease (AD), the hippocampus is affected by pathology and functional impairment early in the disease. Human AD patients have...
by Clinical Neuropsychologist Online | Wednesday, August 21, 2024 | Dementia
Alzheimer’s &Dementia, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: Sarah Walter, Rochelle Long, Cynthia Huling Hummel | August 21,...
by Clinical Neuropsychologist Online | Tuesday, August 20, 2024 | Neurorehabilitation
Neurorehabilitation and Neural Repair, Volume 38, Issue 10, Page 775-790, October 2024. BackgroundBalance training covers a range of different modalities and complexity levels for people with multiple sclerosis (MS). When evaluating the effects of balance training...
by Clinical Neuropsychologist Online | Tuesday, August 20, 2024 | Neurorehabilitation
Neurorehabilitation and Neural Repair, Volume 38, Issue 10, Page 752-763, October 2024. Background and ObjectiveThe biomarkers of hand function may differ based on level of motor impairment after stroke. The objective of this study was to determine the relationship...
